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action of miRNAs in altering the metabolism of cancer 
cells and presents possible therapeutic approaches to 
treating breast cancers that are resistant to current drugs.  
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1  Background 
MicroRNAs (miRNAs) are small, non-coding RNAs, 18-21 
nucleotides in length, which modify gene expression post-
transcriptionally and act as intracellular mediators in 
various biological processes. Because miRNA deregulation 
is a common feature of malignancies, they are arguably 
the most important species of RNA identified in cancer. 
Several studies have shown that, depending on the type 
of cancer, miRNAs can act as either oncogenes or tumor 
suppressors. Some miRNAs have been correlated with 
the prognosis of the disease or detected in serum/plasma 
for diagnostic purposes. Moreover, miRNA signatures are 
associated with tumor subtypes and clinical outcomes, 
suggesting that deregulated miRNAs may represent novel 
therapeutic targets [1, 2]. Various forms of miRNAs are 
differently expressed in subtypes of breast cancer [3, 
4].   According to mRNA profiling, there are at least six 
distinct molecular subtypes of TNBC, and the miRNA 
expression among them may vary. These subtypes include 
luminal androgen receptor (LAR), basal-like ones (BL1 
and BL2), a stem-like (MSL), a mesenchymal (M), and the 
immunomodulatory (IM) subtype [5].    
Although comprehensive clinical data is scanty, 
progress has been made in our understanding of the 
complex molecular events that regulate TNBC metabolic 
phenotypes. miRNAs clearly play critical roles in the 
regulation of cancer cell metabolism through their actions 
on the expression of the genes involved in the  processes. 
Just as miRNA profiles are altered in each subtype of breast 
cancer, specific metabolic profiles are observed in tumors 
to have differing expressions of ER and PgR. For example, 
TNBC shows a significantly higher level of glycolysis 
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Abstract: MicroRNAs (miRNAs) are well known to 
influence the expression of the genes that regulate 
critical cellular functions. Various reports have suggested 
that they play critical roles in breast cancer metabolism 
through the regulation of various metabolic pathways, 
including the metabolism of glucose, lipids, glycolysis and 
the mitochondrial tricarboxylic acid cycle (TCA). miRNAs 
regulate the metabolic process by targeting key molecules 
(enzymes, kinases transporters) or by modifying the 
expression of key transcription molecules. In addition, 
miRNAs can indirectly regulate mRNA translation by 
targeting chromatin-remodeling enzymes. Furthermore, 
miRNAs influence the expression of both oncogenes and 
tumor suppressors and have a major impact on PI3K/AKT, 
HIF, and MYC signal transduction, which contributes 
to the metabolic phenotype in human cancer. Although 
human epidermal growth factor and endocrine therapies 
have been effective in treating breast cancer, for locally 
advanced and distant metastases mortality remains high. 
Drug resistance and recurrence remain major hurdles 
for advanced breast cancer therapy. Given the critical 
influence of metabolic reprogramming in the progression 
of neoplasm, tumorigenesis and metastasis, research 
should focus on novel targets of metabolic enzymes to 
reverse drug resistance and improve overall survival 
rates. Blocking the miRNAs that contribute to metabolic 
reprogramming or the use of exogenous miRNAs as 
antisense oligonucleotides, may be an effective way to 
treat aggressive, chemo-resistant cancers. This review 
summarizes current knowledge on the mechanism of 
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cancer cell proliferation, in part because miRNAs have 
been shown to affect carbohydrate metabolism as well 
as lipid metabolism.  Whether restoring normal aerobic 
metabolism to a cancerous cell could halt the process 
of tumorigenesis and whether miRNAs are involved is 
still under investigation. To date, the evidence suggests 
that miRNAs act directly by interacting with metabolic 
transporters, metabolic enzymes and the vital signaling 
pathways involved in metabolism, and by controlling the 
expression of oncogenes and tumor suppressors. This 
review centers on the crucial roles of miRNAs in modifying 
metabolism in cancer cells.
2  miRNAs mediate metabolic repro-
gramming in breast cancer
Cancerous cells use metabolic reprogramming in order 
to enhance biosynthesis, growth, and survival [14]. The 
metabolic reprogramming of cancer cells is achieved 
through a complex interplay of regulatory networks 
involving phosphatidylinositide 3-kinase (PI3K), mTOR, 
protein kinase B (Akt), PTEN and 5’ AMP-activated protein 
kinase (AMPK). While many miRNAs regulate glucose, lipid 
and the metabolism of amino acids by modulating gene 
transcription, the lack of information on major metabolic 
processes in the mammary glands has meant that 
metabolic reprograming by miRNAs in breast cancer has 
not been studied in detail [8]. It is well known that cancer 
cells use mechanisms of aerobic energy production rather 
than oxidative phosphorylation [7, 15]; most fundamental 
metabolic processes such as increased rates of glucose 
uptake and glycolysis, suppressed gluconeogenesis, 
and lactic acid fermentation are altered. Abnormal 
glucose metabolism is associated with changes in miRNA 
expression and miRNAs have been shown to respond to 
the adaptation of cells to different glucose conditions. For 
example, in mesenchymal stem cells under hyperglycemic 
conditions, there is reduced miR-32-5p synthesis, leading 
to the promotion of the cell cycle by the targeting PTEN. 
In malignant cells, the deregulation of glucose 
transporters (GLUTs) produces a high glucose requirement 
and increased glucose uptake, which accelerates cancer 
cell metabolism. GLUT expression also correlates 
positively with the pathological grade of breast cancer. 
In breast cancer cells, six types of glucose transporters 
can be found: GLUT1, GLUT2, GLUT3, GLUT4, GLUT5, 
and GLUT12. The GLUT1, GLUT2 and GLUT3 transcripts 
are elevated, in many cancers, but surprisingly mRNA for 
GLUT4 and GLUT5 has not been detected. TNBC tumor 
homogenates and also locally advanced breast cancers 
than other types of breast cancer do, and requires higher 
GLUT-1 expression. The Warburg effect is the best-known 
metabolic phenotype observed to date in tumors; this is 
the phenomenon by which cancer cells rely for energy on 
aerobic glycolysis. The dysregulation of miRNAs affects 
the rate of glycolysis [6], and miRNAs such as miR-129, 
which enhances GLUT-1 expression, therefore contributing 
to the Warburg effect [7]. Malignant transformation is also 
associated with excessive glucose uptake, de novo fatty 
acid synthesis, glutaminolysis, altered lipid metabolism, 
aerobic glycolysis, and an increase of reactive oxygen 
species (ROS) [8]. 
The finding that the benign tumors and stromal 
fibroblasts associated with cancer cells also use aerobic 
glycolysis is the basis for the reverse Warburg effect. It has 
been suggested that cancerous epithelial cells can trigger 
fibroblasts to undertake aerobic glycolysis and thus produce 
pyruvate and lactase. These metabolites of glycolysis 
feed the cancer cells, leading to increased proliferation 
[7]. Therefore, many papers highlight the link between 
ROS production, glucose metabolism and the epithelial 
mesenchymal transition (EMT), a feature associated with 
basal cell like breast cancer. Increased malignancy is also 
linked with increased glycolytic metabolism [9, 10]. The 
mechanism(s) remains to be established by which enhanced 
glycolytic activity and increased ROS are activated; the 
latter directly suppresses aerobic glycolysis by inhibiting 
pyruvate kinase (PKM2) and inducing NADPH production. 
This facilitates antioxidant synthesis and thus permits the 
accumulation of glycolytic intermediates [8]. How signaling 
pathways control energy metabolism is an important 
question, since studying metabolic pathways may yield 
new targets in treating drug-resistant and metastatic 
breast cancers [11, 12]. For example, phosphatidylinositol 
3-kinase has a critical role in cancer metabolism. PI3K/Akt 
is thought to be involved in the modulation of FASN, a vital 
enzyme necessary for the de novo synthesis of fatty acids. 
Up-regulation of FASN has been found in premalignant 
lesions and most human cancers.  Cancer cells depend on 
de novo fatty acid synthesis, which is suppressed in normal 
cells having low FASN expression [12, 13]. Interestingly, the 
expression of FASN is regulated negatively by miR-195 via a 
unique binding site in FASN 3’-UTR, which in consequence 
inhibits migration and invasion [13]. In addition, PI3K is 
targeted by miR-123a, miR-136, miR-320, miR-422, and miR-
506, which taken together gives strong evidence for the role 
of miRNAs in regulating cell metabolism.
In order to produce the great amount of ATP necessary 
for cancer cell proliferation, it is necessary to have a 
metabolic shift to aerobic glycolysis (the Warburg effect). 
Research strongly suggests that miRNAs are involved in 
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GLUT1; miR-106a and miR-195-5p target GLUT3; and miR-93 
targets GLUT4 [20]. The increased expression of miR-19a, 
miR-19b and miR-130b has been shown to down-regulate 
GLUT-1. miR-195-5p is a direct regulator of GLUT3, which 
is elevated in most malignant tissues. miR-195-5p inhibits 
cell growth and proliferation, and promotes apoptosis 
by suppressing GLUT3 expression, which suppresses 
proliferation (Figure 1) [6, 21]. This evidence suggests that 
exploiting or silencing miRNAs may open new horizons 
for cancer therapy. 
show an increased expression of GLUTs. Much research 
has unequivocally demonstrated that GLUT1 and GLUT3 
are much higher in many types of tumor [16, 17]. GLUT1 
expression is higher in TNBC than in other subtypes of 
breast cancer [10, 18, 19]. In particular, GLUT1 is believed to 
be an important rate-limiting step in the control of glucose 
transport to cancer cells, but interestingly it is nearly 
undetectable in benign tumors and normal epithelial 
tissue [17]. miRNAs regulate the expression of several of 
the genes that facilitate glucose uptake. miR-129 targets 
 
Figure 1: miRNAs regulate breast cancer cell metabolism. Red bars indicate inhibition of the 
target. The shift to aerobic glycolysis in breast cancer cells is facilitated by miRNAs. MiRNAs 
also regulate the expression of glucose transporters (GLUTs), hexokinase 2 (HK2) enzyme 
which are involved in glycolysis. 
Figure 1: miRNAs regulate breast cancer cell metabolism. Red bars indicate inhibition of the target. The change to aerobic glycolysis in 
cancer cells of the breast is facilitated by miRNAs, which also regulate the expression of GLUT transporters and the hexokinase 2 (HK2) 
enzyme involved in glycolysis.
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order to fulfill the high-energy demands of cancer cells, 
the solute carrier family 16 member 1 (SLC16A1) is targeted 
by miR-124, which directly regulates the formation of 
lactate by the overexpression of SLC16A1. In human breast 
cancer miR-210 also indirectly improves aerobic glycolysis 
by repressing mitochondrial respiration. The expression 
of miR-200a is reduced in breast cancer and the level of 
mitochondrial transcription factor A (TFAM) is increased. 
TFAM directly activates mitochondrial respiration and 
regulates both the production of ROS and mitochondrial 
oxidation[31].
2.2  Role of miRNA in TCA Cycle 
Though cancer cells usually prefer aerobic glycolysis for 
the production of energy to the TCA cycle, the TCA cycle 
also provides cancer cells with energy and is targeted 
by miRNAs. A shift of glucose metabolism to aerobic 
glycolysis is common in cancer cells. Studies predict that 
miR-107 and miR-103 will up-regulate pantothenate kinase 
(PanK). PanK expression is essential to the coenzyme 
A pathway and it catalyzes the phosphorylation of 
pantothenate to 4’-phosphopantothenate. Acetyl CoA 
and lipid levels are regulated by miR-103 and miR-107[6, 
32, 33]. In addition, miR-19a, miR-19b, miR-122a, miR-
148a, miR-152, miR-299-5p, miR-421, and miR-494 regulate 
the genes that encode TCA enzymes [6]; the first miRNA 
linked to metabolic control was miR-122. miRNAs are also 
important players in the control of the TCA cycle in that 
modulate transcription factors in breast cancer such as 
the myelocytomatosis oncogene (MYC) and the hypoxia 
inducible factors HIF1-α and HIF1-β [6]. 
2.3  Role of miRNAs in homeostasis and 
metabolism of lipids
Cancer metabolism varies according to both the metastatic 
site and the expression of proteins such as the fatty 
acid synthase (FASN) which are associated with lipid 
metabolism. Research has revealed the overexpression of 
FASN in breast cancer cells, facilitating their development 
and survival. miR-142-3p, miR-195, miR-320, and miR-424 
were found to inhibit FASN [39, 40]. The first miRNA found 
to be associated with lipid metabolism was miR-122 [34], 
which has been implicated in the increased synthesis of 
lipids and cholesterol-rich membranes in cancer cells [35]. 
The inhibition of miR-122 (a tumor suppressor) disrupts 
lipid storage and lipid metabolism in breast cancer cells 
[8, 32, 41]. In addition, glutathione S-transferase Pi 1 
2.1  Role of miRNAs in glycolysis
Apart from glucose transport, glycolysis also provides 
cancer cells with energy. A number of studies have 
suggested that miRNAs control glycolytic enzymes and 
thus the regulation of irreversible steps in glycolysis. 
The target enzymes include 6-phosphofructo-1-kinase 
(PFK1), hexokinase (HK) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). It is known that the human 
genome encodes four HK isoforms, HK1, HK2, HK3, 
and HK4. HK2 is the key component of the Warburg 
effect, and a promising target for novel therapy. miR-143 
inhibits glycolysis by down-regulating HK2, a glycolytic 
enzyme that converts glucose to glucose-6-phosphate. 
This mechanism was confirmed for breast cancer by 
Fang in 2012 [22] and in colon cancer by Gregersen in 
2012 [23]. Many reports have shown that miR-143 targets 
HK2 and thus regulates the metabolism of glucose in 
cancer, indicating that it may become a novel target for 
cancer chemotherapy. Interestingly, miR-155 has been 
found to repress miR-143 by action on C/EBPβ, which is a 
transcriptional activator of mir-143, and to up-regulate HK2 
expression at the post-transcriptional level.  In addition, 
administration of cholesterol-modified agomiR-143 
(systemic delivery) significantly inhibited tumor growth 
in TNBC mice, suggesting a potential therapeutic regimen 
for TNBC [24]. miR-155 is known to control the expression 
of HK2 in breast cancer cells through a dual-switch 
mechanism. Initially, miR-155 represses miR-143, which 
negatively regulates HK2. Then, miR-155 stimulates HK2 
transcription through the activation of STAT3, by down-
regulating SOCS1, a STAT3 inhibitor in breast cancer cells 
[17, 25, 26]. Another important enzyme associated with 
breast cancer cell metastasis is phosphoglucose isomerase 
(PGI), which has been implicated with the metastasis 
and invasion. PGI, a cytosolic enzyme that catalyzes the 
interconversion of glucose-6-phosphate and fructose-6-
phosphate, plays a fundamental role in gluconeogenesis 
and glycolysis. PGI regulates miR-200 family expression, 
which directly affects the EMT in breast cancer [8, 27]. 
In contrast to the intracellular level of miR-122, which 
does not significantly differ whether metastatic or non-
metastatic, the level of exosomal (circulating) miR-122 is 
correlated with the metastatic capacity of breast cancer 
[28, 29]. Exosomal miR-122 inhibits glucose uptake by 
downregulating PKM2 leading to enhanced cancer cell 
proliferation [29, 30]. PKM2 allows the tumor to use 
phospho-metabolites, which are essential precursors 
involved in the synthesis of amino acids. During aerobic 
glycolysis, lactate dehydrogenase (LDH) is transported out 
of cells by the monocarboxylate transporter 1 (MCT1). In 
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3  miRNAs Therapeutics in breast 
cancer metabolism
For the treatment of drug-resistant breast cancer, 
targeted metabolic reprogramming by miRNAs may be a 
novel and promising anti-cancer therapy. To effectively 
treat breast cancer, drugs that target metabolic enzymes 
and their regulators (miRNAs) may help to overcome 
difficulties in treatment [47]. miRNAs have been shown 
to be therapeutically effective in managing cancer. One 
study showed that suppressing glucose and glycolysis 
by inhibiting HK and blocking GLUTS can improve 
breast cancer therapy [43]. Another study revealed that 
a tumor suppressor p53 pathway induces let-7, miR-34, 
miR-107, and miR-200, which regulate MYC, LDHA, and 
sirtuin 1 (SIRT1) [32]. Targeting LDHA, MYC, SIRT1, 
and other metabolic pathways with miR34 may be an 
effective and innovative therapy for breast cancer. 
Moreover, it has been demonstrated that metformin 
plays a pivotal role in reprogramming cancer cell 
metabolism and directly modulating genes and miRNAs 
[48]. Metformin acts by affecting the progression and 
relapse of different types of cancer when combined with 
a chemotherapeutic agent. The anticancer metabolic 
actions of metformin involves miRNA modulation [8, 
49]. Several studies have shown that the systematic 
administration of miRNAs helps to counter the growth 
of breast cancers and to reduce cell toxicity. miR-34 
expression in breast cancer is decreased as it is in other 
types of cancer [43]. These miRNAs have important 
tumor suppression functions and negatively regulate 
oncogenes by targeting RAS and MYC [32]. 
(GSTP1) is a potent regulator of lipid metabolism in TNBC. 
In prostate cancer, miRNAs have been found to regulate 
GSTP1 [42], suggesting evidence for the role of miRNAs in 
TNBC tumorigenesis. One study showed that inactivation 
of GSTP1 reduces tumorigenesis activity in TNBC [43]. 
Thus, targeting lipid metabolism via exogenous miRNAs 
may be a novel therapeutic strategy for combating TNBC. 
2.4  Role of miRNAs in signaling pathways 
involved in cancer metabolism 
Signaling pathways that have been deregulated, including 
PI3K/Akt/mTOR, AMPK, c-Myc and HIF, are hallmarks of 
cancer cells [32, 44]. The relationship between imbalanced 
signaling pathways and deregulated miRNAs is associated 
with the abnormal metabolism of cancer cells. The major 
pathways associated with the metabolic reprogramming 
of breast cancer cells include PI3K/AKT/mTOR and 
PTEN. In breast cancer, the expression of glycolytic 
enzymes and the translocation of glucose transporters 
cause an increase in glycolysis via the AKT pathway. In 
turn, activating the AKT pathway regulates metabolism 
via HIF-1α [8, 32, 44]. Studies have also shown that AKT 
isoforms regulate miRNAs, for example, the miR-200 
family in breast epithelial cells, such that their expression 
is reduced with activated AKT2 [45]. The p53 pathway may 
inhibit the expression of GLUT-1 and GLUT-4 thus affecting 
glycolysis, and can also activate hexokinase 2 (HK2) [6, 46]. 
To date, miR-25, miR-29, miR-30d, miR-34a, miR-125b, miR-
142, miR-194, and miR-215 are known to control the activity 
and abundance of p53 [6]. Of these, miR-25, miR-30d, and 
miR-125b negatively regulate p53 by directly binding to the 
3’-UTR of p53 mRNA, whereas the other molecules modify 
the regulators of p53, such as  MDM2 [6]. 
Table 1: MicroRNAs, target pathways, and gene regulation of breast cancer metabolism.
miRNAs Target genes Metabolic activity/Pathway References
miR-210 ISCU Hypoxia, Krebs cycle, glycolysis [34] 
ISCU, COX10 Hypoxia, ROS, glycolysis [35]
SDHD, NDUFA4 HIF-1α, ROS, TCA cycle, Hypoxia [34]
miR-155/miR-143 HK2 Aerobic glycolysis [25]
miR-378 ESRRG, GABPA, ERR Oxidative phosphorylation [36]
miR-124 SLC16A1 Aerobic glycolysis [37]
miR-200 PGI Glycolysis [27]
miR-126 PI3K Down-regulation [38]
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4  Conclusion 
Current research on miRNAs as major regulators of cancer 
metabolism provides a foundation for understanding the 
mechanisms responsible for the aberrant metabolism 
of cancer cells. Collectively, the data described in this 
mini-review support the hypothesis that miRNAs act to 
modulate the glucose metabolism by regulating vital 
factors including the transporters (GLUT) or key enzymes 
(HK2, PKM2). The addition of exogenous miRNAs or the 
silencing of specific miRNAs may be capable of halting 
metastasis. These findings provide future directions 
for the targeting of metabolic enzymes, which may be a 
promising strategy for overcoming drug-resistant cancers. 
It remains clinically challenging to control breast cancer in 
patients who are resistant to chemotherapy. More research 
is needed on whether the circulating and extracellular 
miRNAs are involved in cancer metabolism or in regulating 
the key glycolytic genes. It is also important to find which 
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